Publications by authors named "M Hausschild"
Background: Hip abductor tear (HAT) is an increasingly diagnosed cause of refractory lateral hip pain and dysfunction, affecting 10-25% of the general population.
Purpose: (1) to determine the rate of return to activity and to assess the physical and recreational activity of patients undergoing open hip abductor repair (oHATr) and (2) to describe the modification or initiation of new sports disciplines.
Study Design: Case series; Level of evidence, 4.
Article Synopsis
- The study focuses on breast cancer patients receiving neoadjuvant chemotherapy (NACT) and examines how certain clinical and pathological characteristics relate to residual axillary involvement after treatment.
- The analysis included 360 patients with clinically occult nodal metastases, identifying that 22.3% still had involved lymph nodes after NACT and 22.3% achieved a pathological complete remission (pCR) in the breast.
- Significant associations were found between factors like extranodal spread, absence of multifocality, and pCR in the breast with residual axillary disease; notably, triple-negative and HER/2 positive patients showed a very low risk of residual axillary involvement if they achieved a breast pCR.
Optimization of axillary staging among patients converting from clinically node-positive disease to clinically node-negative disease through primary systemic therapy is needed. We aimed at developing a nomogram predicting the probability of positive axillary status after chemotherapy based on clinical/pathological parameters. Patients from study arm C of the SENTINA trial were included.
View Article and Find Full Text PDFBackground: The optimum timing of sentinel-lymph-node biopsy for breast cancer patients treated with neoadjuvant chemotherapy is uncertain. The SENTINA (SENTinel NeoAdjuvant) study was designed to evaluate a specific algorithm for timing of a standardised sentinel-lymph-node biopsy procedure in patients who undergo neoadjuvant chemotherapy.
Methods: SENTINA is a four-arm, prospective, multicentre cohort study undertaken at 103 institutions in Germany and Austria.
Background: The present investigation aimed at assessing the possibility of distinguishing between malignant and benign breast lesions by measuring the signal intensity in vessels of the suspect lesions over time after administration of the ultrasound contrast agent Levovist.
Materials And Methods: Levovist was administered intravenously to 21 patients with breast cancer and 12 patients with a benign breast lesion. In the subsequent ultrasound investigation (Color Power Angiography) the resulting increase in brightness over time in the vessels of the lesions was measured using the videodensitometry method.